This is a phase I/II open-label clinical trial determining the optimal biological dose (OBD) of N-acetylcysteine in subjects with myeloproliferative neoplasms. These are subjects who have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF).
© 2026 Paid Trials | All Right Reserved.
Step 1: Add a recruitment campaign (optional)
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites
Your plan includes posting your clinical trials on our recruitment portal and mobile apps. Boost your trials with targeted advertising campaigns to reach more participants, faster.
We handle everything: audience targeting, creative development, geo targeting to your site locations, and ongoing optimizations. Qualified participant inquiries flow directly into your dashboard. Inquiries typically begin within a few days and continue throughout the campaign.
